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Abstract:  1 
Background & Aims: A 3-dimensional (3D) culture system for immortalized 2 
human hepatocytes (HuS-E/2 cells) was recently shown to support the lifecycle 3 
of blood-borne hepatitis C virus (HCV). We used this system to identify proteins 4 
that are active during the HCV lifecycle under 3D culture conditions.  5 
Methods: We compared gene expression profiles of HuS-E/2 cells cultured 6 
under 2D and 3D conditions. We identified signaling pathways that were 7 
differentially activated in the cells, and analyzed their functions in the HCV 8 
lifecycle using a recombinant HCV-producing cell culture system, with small 9 
interfering (si)RNAs and chemical reagents. We investigated the effects of anti-10 
HCV reagents that altered these signaling pathways in mice with humanized 11 
livers (carrying human hepatocytes). 12 
Results: Microarray analysis showed that cells cultured under 2D vs 3D 13 
conditions expressed different levels of mRNAs encoding prostaglandin 14 
synthases. siRNA-mediated knockdown of thromboxane A2 synthase (TXAS) 15 
and incubation of hepatocytes with a TXAS inhibitor showed that this enzyme is 16 
required for production of infectious HCV, but does not affect replication of the 17 
HCV replication or particle release. The TXAS inhibitor and a prostaglandin I2 18 
receptor agonist, which has effects that are opposite those of TXA2, reduced 19 
serum levels of HCV and inhibited the infection of human hepatocytes by blood-20 
borne HCV in mice. 21 
Conclusions: An inhibitor of the prostaglandin synthase TXAS inhibits 22 
production of infectious HCV particles in cultured hepatocytes and HCV 23 
infection of hepatocytes in mice with humanized livers. It might therefore be 1 
developed as therapeutic for HCV infection. 2 
Keywords: infectious virus particle; lipid mediator; antiviral drug 3 
Introduction 1 
Approximately 170 million people worldwide are infected with hepatitis C 2 
virus (HCV)1, with the majority suffering from chronic hepatitis, liver cirrhosis, 3 
and/or hepatocellular carcinoma2. HCV is currently treated using a combination 4 
of polyethylene glycol–conjugated interferon (peg-IFN) and ribavirin, although 5 
no more than 60% of individuals adequately respond3. Recently, inhibitors of 6 
HCV nonstructural proteins have been developed as direct-acting anti-viral 7 
agents (DAA) to treat HCV effectively4-6. However, HCV often acquires the 8 
resistance against the treatment with DAA in case of monotherapy7. Current 9 
efforts are therefore focused on better understanding the lifecycle of HCV to find 10 
the cellular target of novel anti-HCV drug to use the various therapeutic options. 11 
A cell culture system that allows the production of recombinant infectious 12 
HCV, called HCVcc, was recently developed using a cloned HCV genome and 13 
the hepatocellular carcinoma–derived Huh-7 cell line8-10. Experiments using the 14 
culture system have provided novel insights on the HCV lifecycle such as 15 
finding the production of infectious HCV particles near lipid droplets (LDs) and 16 
endoplasmic reticulum–derived LD-associated membranes11. Huh-7 cells, 17 
however, only allow the proliferation of recombinant HCV, and not blood-borne 18 
HCV (bbHCV).  19 
To study the lifecycle of bbHCV, we cloned immortalized human hepatocyte 20 
(IHH), HuS-E/2 cells, which permitted some degree of bbHCV infection12. 21 
Integrating hollow fibers into the three-dimensional (3D) culture system resulted 22 
in efficient continuous proliferation of infected HCV production from the cells13. 23 
Using the improved system, we previously compared the gene expression 1 
profiles of HuS-E/2 cells under the 2D and 3D culture conditions using 2 
microarray analysis. This allowed us to identify signaling pathways that 3 
contribute to the proliferation of HCV, for example, peroxisome proliferator–4 
activated receptor α signaling that enhances HCV replication14. This result was 5 
confirmed by other groups15, 16, corroborating that our strategy can uncover 6 
cellular events that support the proliferation of HCV. We, therefore, 7 
hypothesized that leveraging the in vitro systems described above may help 8 
elucidate the molecular mechanisms underlying the HCV lifecycle. 9 
Prostanoids are metabolites of the arachidonic acid cascade (AAC) that 10 
possess various physiologic activities17. These metabolites include 11 
prostaglandin (PG) E2, D2, I2, and F2, and thromboxane A2 (TXA2)17. Although 12 
several studies have shown that PG signaling contributes to liver regeneration18, 13 
19, the physiologic functions of these lipid mediators in human hepatocytes are 14 
still unknown. Interestingly, one report showed that PGE2 might support HCV 15 
genome replication in cells bearing self-replicating HCV subgenomic replicon 16 
RNA20. Whether prostanoids are involved in the HCV lifecycle, however, has not 17 
been precisely investigated.  18 
In this study, we provide evidence that TXA2 synthase (TXAS) is involved in 19 
the formation of infectious HCV, by cell culture system, and that a TXAS 20 
inhibitor and PGI2 receptor (IP) agonist that has opposite physiological effects to 21 
TXA2 can be used as novel anti-HCV drugs, by using chimeric mice bearing 22 
transplanted human hepatocytes21. This is the first report showing the 23 
contribution of the AAC to HCV infectivity and the potency of a prostanoid as an 1 
anti-viral agent. 2 
Materials and Methods. 1 
Cell culture 2 
The human hepatocellular carcinoma–derived Huh-7 and Huh-7.5 cell lines 3 
were cultured as described previously22. HuS-E/2 cells are IHH transduced with 4 
E6 and E7 genes of human papilloma virus 18 and human telomerase reverse 5 
transcriptase gene as described previously12. 2D and 3D culture conditions for 6 
HuS-E/2 cells were as described previously12. 7 
 8 
Reagents and antibodies 9 
FR122047, PGH2, ONO1301, daltroban, and dibutyryl cyclic adenosine 10 
monophosphate (cAMP) sodium salt were purchased from Sigma-Aldrich 11 
(Missouri, USA). Cyclooxygenase (COX)-2 inhibitor 1 and Ozagrel were 12 
purchased from Santa Cruz Biotechnology (California, USA). U-46619 was 13 
purchased from Cayman Chemical (Michigan, USA). Beraprost was a generous 14 
gift from Toray Co. (Tokyo, Japan). FR122047, PGH2, ONO1301,	 Daltroban, 15 
COX-2 inhibitor1, Ozagrel, Beraprost, and Calucium ionophore were dissolved 16 
in DMSO. U-46619 and TXB2 were dissolved in methyl acetate.  Dibutyryl cAMP 17 
was dissolved in water. The effect of each reagent on cell viability was analyzed 18 
using a Cell Proliferation Kit 2 (Roche, Basel, Switzerland) based on the 19 
manufacturerʼs instruction. An antibody specific for Core protein (antibody 32-1) 20 
was a gift from Dr. Michinori Kohara (Tokyo Metropolitan Institute of Medical 21 
Science, Tokyo, Japan). Rabbit polyclonal anti-NS5A protein CL1 antibody and 22 
anti-HCV protein antibody in human serum were described previously11. 23 
 1 
Microarray analysis 2 
Total RNA purified from HuS-E/2 cells cultured under 2D or 3D conditions in the 3 
absence of HCV infection was analyzed with a 3D-Gene human chip 25k (Toray, 4 
Tokyo, Japan) to compare gene expression profiles as described previously14. 5 
The accession number of the results is as “E-MTAB-1491” in ArrayExpress. 6 
 7 
Production of HCVcc and sample preparation 8 
HCVcc was produced from the Huh-7 or Huh-7.5 cells transfected with in vitro 9 
synthesized JFH1E2FL or J6/JFH1 RNA as described previously11. The 10 
transfected cells and culture medium were harvested at four days post-11 
transfection. For JFH1E2FL RNA-transfected Huh-7 cells treated with TXAS-12 
specific small interfering RNA (siRNA), cells and culture medium were 13 
harvested at 3 days post-transfection. Culture medium including HCVcc was 14 
concentrated used for infection experiments as described previously11. 15 
Concentrated culture medium from JFH1 RNA-transfected Huh-7 cells was 16 
fractionated as described previously11. Infectivity titer in each fraction was 17 
analyzed by focus-formation assay, which was determined by the average 18 
number of HCV-positive foci. 19 
 20 
Reverse transcriptase polymerase chain reaction (RT-PCR) and 21 
quantitative RT-PCR (qRT-PCR) 22 
Total RNA was isolated from the cells and medium using Sepasol I Super and 1 
Sepasol II (Nacalai Tesque), respectively, according to the manufacturerʼs 2 
instructions. Using 200 ng of total RNA as a template, we performed RT-PCR 3 
and qRT-PCR with a one-step RNA PCR kit and one-step SYBR Primescript 4 
RT-PCR kit 2  (Takara, Shiga, Japan), respectively, according to the 5 
manufacturerʼs instructions. Information on both experiments was shown in 6 
Supplemental Table 1 and 2.  7 
 8 
Infection of HCVcc 9 
Infection experiment of HCVcc and detection of infected Huh-7.5 cells by 10 
indirect immunofluorescence analysis were performed mainly as described 11 
previously11. The number of infection positive cells detected in 4 x 104 target 12 
cells one day after infection with HCVcc including 107 copies of RNase resistant 13 
HCV genome was defined as the specific infectivity in the infection experiments 14 
in our protocol. 15 
 16 
Indirect immunofluorescence analysis 17 
HCV proteins were examined in cells using a Leica SP2 confocal microscope 18 
(Leica, Heidelberg, Germany) and infected cells were counted using a BioZero 19 
fluorescence microscope (Keyence, Tokyo, Japan).  20 
 21 
Preparation of intracellular HCV particles  22 
Intracellular HCV particles were prepared as described previously23 23 
 1 
Pharmacological test in chimeric mice bearing transplanted human 2 
hepatocytes 3 
All mouse studies were conducted at Hiroshima University and accorded with 4 
the guidelines of the local committee for animal experiments. Chimeric mice 5 
transplanted with human hepatocytes were generated as described previously21. 6 
The experimental protocol was approved by the Ethics Review Committee for 7 
Animal Experimentation of the Graduate School of Biomedical Sciences 8 
(Hiroshima University). The reagents were first administered 1 week after the 9 
chimeric mice were infected with 1.0 x 105 titer of bbHCV. ONO1301 was 10 
injected subcutaneously at a dose of 200 µg per mouse. Beraprost and Ozagrel 11 
were orally administrated at a dose of 10 µg and 300 µg per mouse, 12 
respectively. For positive control experiment, Telaprevir was administrated as 13 
described previously24. All reagents were administrated twice each day. Serum 14 
samples were collected at 2, 3, and 4 weeks after starting the treatments. HCV 15 
RNA levels in the samples were evaluated in quantitative RT-PCRs. 16 
 17 
Statistical Analyses of Data  18 
The significance of differences in the means was determined by Studentʼs t test 19 
or Wilcoxon signed-rank test (Fig. 7 and Supplemental Fig. 14). 20 
 21 
Results 22 
Expression of PG synthase mRNA in HuS-E/2 cells cultured under 3D 1 
conditions 2 
To identify signaling pathways that contribute to HCV proliferation under the 3D 3 
culture conditions, we compared the gene expression profiles of 2D- and 3D- 4 
cultured HuS-E/2 cells as described previously14. We found that the expression 5 
of 984 genes was up-regulated more than two times in both of two types of 3D-6 
cultured HuS-E/2 cells, and that of 1491 genes was down-regulated less than 7 
half time. For the two 3D conditions, we identified the expression of a set of 8 
genes encoding enzymes of the AAC. The expression levels of mRNAs for AAC 9 
enzymes, COX1, PGD2 synthase, and TXAS increased in HuS-E/2 cells 10 
cultured under the 3D conditions (Fig. 1A), while those for PGE2 and PGI2 11 
synthases (PGIS) decreased (Fig. 1A). These results were confirmed by qRT-12 
PCR analysis (Fig. 1A, gray bars). The relative protein levels of those enzymes 13 
in 2D and 3D cultured HuS-E/2 cells reflected the quantitative difference of 14 
those mRNAs, except PGDS (Fig. 1B). The expression of those genes and the 15 
production of those proteins were also observed in the liver tissues from 16 
patients with hepatitis C, suggesting the functional roles of those products in the 17 
human liver (Supplemental Fig. 1). 18 
 19 
The AAC contributes to infectious HCV production 20 
To assess whether the AAC plays roles in the HCV lifecycle, the contributions of 21 
the AAC rate-limiting enzymes COX1 and COX2 were examined using the JFH1 22 
cell culture system. We first investigated the role of COX1, of which gene is 23 
known to be a constitutively expressed in general, by adding the COX1 inhibitor 1 
FR122047 to JFH1 RNA–transfected cell cultures. Even at the higher 2 
concentrations, FR122047 did not markedly affect the amount of HCV RNA in 3 
the medium or cells (Fig. 2A, black and white bars) with a little cytotoxicity at 10 4 
µM. Nevertheless, FR122047 dose-dependently decreased the infectivity of 5 
HCVcc in the culture medium (Fig. 2B, C). As the infection experiment using 6 
lower titer of HCVcc from inhibitor treated cells showed that the inhibitor 7 
affected the number of infection positive focus but not the number of the cells in 8 
a focus (Fig. 2C), the treatment of COX1 inhibitor seemed to decrease the 9 
focus-forming ability of HCVcc. Next, the contribution of inducible COX2 was 10 
examined using COX2 inhibitor 1. The inhibitor, however, did not affect the 11 
infectivity of HCVcc in the medium (Supplemental Fig. 2A, B), probably because 12 
of the lack of COX2 gene expression in Huh-7 cells (Supplemental Fig. 2C and 13 
3A). These data suggested that COX1 and the AAC play a role in infectious 14 
HCVcc production without significant effects on HCV genome replication or 15 
particle release from the cells.  16 
 17 
TXAS plays a key role in infectious HCV production 18 
To further examine the contribution of the AAC to infectious HCVcc production, 19 
we focused on TXAS, because, like COX1 mRNA, TXAS mRNA levels 20 
increased in HuS-E/2 cells cultured under 3D conditions. Although PGD2 21 
synthase mRNA levels also increased, this synthase was unlikely to contribute 22 
to these processes because we did not detect PGD2 synthase mRNA in Huh-7 23 
cells in the JFH1 cell culture system (Supplemental Fig. 3A). Using siRNA- and 1 
shRNA-mediated suppression of mRNA expression, we found that reducing 2 
TXAS mRNA levels in HCVcc-producing Huh-7 cells did not significantly affect 3 
the amount of HCV RNA in the medium or cells (Fig. 3B and Supplemental Fig. 4 
4B, black and white bars), whereas HCVcc in the medium was less infectious, 5 
as was observed when the cells treated with FR122047 (Fig. 3C and 6 
Supplemental Fig. 4C). Treatment with the TXAS inhibitor Ozagrel also dose-7 
dependently suppressed infectious HCVcc production without significantly 8 
affecting HCV RNA levels in the medium or cells (Fig. 3D, E). Similar effects of 9 
Ozagrel were observed in another HCV cell culture system using Huh-7.5 cells 10 
and chimeric recombinant J6/JFH1 HCV, which encoded different structural 11 
proteins from JFH19 (Supplemental Fig. 5), indicating that our results were not 12 
specific to the JFH1 cell culture system. Furthermore, the treatment with PGH2, 13 
a product of COX1 and a substrate of TXAS, showed to increase the infectivity 14 
of HCVcc without effect on the HCV replication and egression despite short half-15 
life of PGH2 (Supplemental Fig. 6). These data suggested that the AAC, in 16 
particular TXAS activity and probably TXA2 produced from PGH2 by TXAS 17 
activity, contributes to infectious HCV production.  18 
 19 
TXA2 receptor (TP) is not required for TXAS-dependent regulation of 20 
infectious HCV production 21 
TXA2 exerts its physiologic functions through TP on plasma membranes17. To 22 
examine the contribution of TXA2/TP signaling, we investigated the effects of 23 
the TP agonist U-46619 in our system. Regardless of dose, however, U-46619 1 
did not affect infectious HCVcc production in the culture system (Supplemental 2 
Fig. 7A, B). Treating Huh-7–derived cell lines with the TP agonist did not 3 
increase the calcium ion concentration—a major downstream effect of TXA2/TP 4 
signaling—even though the activity of U-46619 was confirmed in HEK293 5 
cells17 (Supplemental Fig. 8A). We also evaluated the activity of U-46619 in 6 
terms of TP dependent-activation of Rho and observed the Rho-dependent 7 
stress fiber formation induced with U-46619 in HEK293 cells (Supplemental Fig. 8 
8B). In addition, the level of TP mRNA was, if any, quite low in human 9 
hepatocyte derived cells and PHH, although the only a small amount of the 10 
mRNA was detected in HuS-E/2 cells (Supplemental Fig. 3B). These data 11 
suggested that TXA2/TP signal transduction is deficient in Huh-7–derived cell 12 
lines.  13 
To determine whether TP on the Huh-7 cells was saturated with endogenous 14 
TXA2 ligand, we examined the effects of U-46619 in the presence of Ozagrel. U-15 
46619, however, did not rescue the Ozagrel-mediated suppression of infectious 16 
HCVcc production (Fig. 4A, B). Additionally, the TP antagonist daltroban did not 17 
affect infectious HCVcc production (Fig. 4C, D). These data indicated that TP-18 
mediated signaling is not involved in TXAS-dependent regulation of infectious 19 
HCVcc production. Additionally, we examined whether thromboxane B2 20 
(TXB2)—a stable metabolite of TXA2 that does not activate TP—could be used 21 
to replace TXAS during infectious HCVcc production. TXB2 did not counteract 22 
the effects of Ozagrel (Fig. 4A, B), and did not by itself affect the HCV lifecycle 23 
(Supplemental Fig. 7A, B). These data suggested that TXA2 or an unidentified 1 
metabolite of TXA2 acts as a TP-independent regulator of infectious HCV 2 
production (see Discussion). 3 
 4 
TXAS-derived signaling contributes to HCV infectivity 5 
A previous study revealed that infectious HCV is produced near LDs to which 6 
HCV proteins are recruited6. As shown in Fig. 5A, inhibiting TXAS did not 7 
markedly affect the locations of the viral proteins Core and NS5A around LDs, 8 
suggesting that TXAS-derived signaling does not contribute to the recruitment of 9 
HCV proteins to the LDs. Next, to examine whether TXAS-mediated signaling 10 
drives the egression of infectious HCVcc from the cells, we analyzed 11 
intracellular HCVcc in cells treated with Ozagrel. Levels of intracellular HCVcc 12 
RNA in Huh-7 cells treated with or without Ozagrel were equivalent (Fig. 5B). 13 
Nevertheless, the infectivity of intracellular HCVcc from the cells treated with 14 
Ozagrel was markedly decreased as was that of HCVcc in the medium (Fig. 5C). 15 
This result indicated that TXAS-derived signaling is not involved in the release 16 
of infectious HCV particles. Taken together, it seemed likely that TXAS-derived 17 
signaling plays a role on infectious particle formation in the cells. 18 
 19 
Inhibition of TXAS changes the physicochemical properties of HCVcc 20 
We next analyzed HCVcc produced from cells treated with Ozagrel using 21 
sucrose density gradient ultracentrifugation. As reported previously11, two types 22 
of fractions containing either highly infectious, low-density HCVcc (peak fraction 23 
no. 6) or less infectious, high-density HCVcc (peak fraction no. 5) were obtained 1 
using samples derived from cells without treatment with Ozagrel, indicating that 2 
infectious HCVcc was mainly present in fraction no. 6 (Fig. 6, white bars, upper 3 
and lower panels). On the other hand, analyzing Ozagrel-treated cells revealed 4 
decreased levels of HCV RNA in fraction no. 6 (Fig. 6, solid lines, upper and 5 
lower panels). Of note, the amount of HCV RNA in fraction no. 5 remained 6 
similar with or without Ozagrel treatment (Fig. 6, lower panel). These results 7 
suggested that inhibition of TXAS-mediated signaling changed the 8 
physicochemical characteristics of HCVcc, resulting in altered infectivity.  9 
 10 
A TXAS inhibitor and IP agonists inhibit early HCV expansion in bbHCV-11 
infected chimeric mice  12 
Finally, we examined the in vivo anti-HCV effects of a TXAS inhibitor using 13 
bbHCV and uPA/SCID mice bearing transplanted human hepatocytes. The IP 14 
agonist Beraprost was also tested, because PGI2 produces effects opposite to 15 
TXA2 during several physiologic processes, including vascular constriction in 16 
humans25. Both drugs delayed the increase in serum levels of HCV RNA (Fig. 7). 17 
Of note, even 4 weeks after treatment, Beraprost reduced serum HCV RNA 18 
levels to less than a quarter of those observed in control mice (Fig. 7). Our 19 
results indicated that these drugs may inhibit HCV proliferation in vivo, and that 20 
inhibition of TXAS-derived signaling and activation of IP-mediated PGI2 21 
signaling can control HCV proliferation. Although we examined the effects of the 22 
PGIS and IP agonist on the HCV lifecycle using the HCVcc-producing cell 23 
culture system, Beraprost did not result in any notable changes (Supplemental 1 
Fig. 9). To examine whether the Huh-7 cells respond to the IP agonist, we 2 
assessed cAMP signaling using a plasmid bearing cAMP responsive elements 3 
in a promoter upstream of the luciferase gene; cAMP signaling is a major 4 
intracellular signaling pathway that is activated by IP agonists. The IP agonist, 5 
however, did not activate cAMP signaling in Huh-7 cells even though the 6 
pathway was activated in HuS-E/2 cells.  7 
As another candidate anti-HCV drug, we examined the effect of ONO1301, 8 
possessing both TXAS inhibitor and IP agonist activities, in the humanized 9 
chimeric mice. ONO1301 produced the most robust suppression of HCV 10 
infections (Fig. 7). The effects of ONO1301 were also studied in the HCVcc-11 
producing cell cultures; like Ozagrel. ONO1301 suppressed infectious HCV 12 
production (Supplemental Fig. 10), although ONO1301 did not activated cAMP 13 
signaling in Huh-7 cells (Supplemental Fig. 11). Slight decrease of HCVcc 14 
egression, however, caused by the treatment with ONO1301 at high 15 
concentrations might be of note. These results further supported our conclusion 16 
that TXAS-mediated signaling contributes to infectious HCV production, 17 
although the functional role of PGI2 in this process is still unknown. 18 
Discussion 1 
In this study, we showed that TXAS is involved in the development of infectious HCV. 2 
Administration of a TXAS inhibitor inhibited early stages of HCV proliferation post-3 
infection in a chimeric mouse model. These results suggest that TXAS-mediated 4 
infectious HCV production is a potential target for novel anti-HCV therapies. 5 
We first found that inhibiting COX1 and TXAS decreased the infectivity of HCVcc in the 6 
culture medium without any significant effects on viral genome replication and particle 7 
egression (Fig. 2 and 3). In addition, we showed that inhibition of TXAS did not affect 8 
the release of infectious HCVcc from the cells (Fig. 5). Thus, we concluded that TXAS 9 
probably regulates HCV particle maturation and the development of infectivity. 10 
Knockdown of apolipoprotein E, heat shock protein 70, and annexin A2 expression was 11 
previously shown to inhibit infectious HCVcc production26. Of note, decreased 12 
expression of these host factors reduced the production of HCVcc in the culture medium 13 
as well as intracellular HCVcc levels in HCVcc-producing cells, suggesting that TXAS is 14 
playing a different role in HCVcc production. Moreover, our results suggest that TXAS is 15 
the first host factor that has been shown to contribute only to the development of HCV 16 
infectivity.  17 
A previous study reported that infectious HCVcc is produced near LDs11. The HCV 18 
proteins Core and NS5A are located on and nearby LDs, respectively, suggesting a role 19 
in the production of infectious HCVcc11. Because LD localization of these proteins was 20 
not affected by the TXAS inhibitor (Fig. 5A), TXAS is probably required after these viral 21 
proteins are recruited to LDs.  22 
Several studies have shown that the buoyant density of infectious HCVcc differs 1 
slightly from that of noninfectious HCVcc11, 27, 28. Infectious and noninfectious HCVcc are 2 
found in lower and higher density fractions, respectively. In the present study, inhibition 3 
of TXAS reduced the amount of HCVcc in the lower density fraction (fraction 6) 4 
containing the infectious particles, whereas levels of primarily noninfectious HCVcc 5 
particles in the higher density fraction (fraction 5) were not affected (Fig. 6). These 6 
results mirrored previously reported data about NS5A mutant HCVcc, which do not 7 
produce infectious particles11. These results suggested that TXAS might be required to 8 
produce infectious HCVcc near the LDs.  9 
Studies with treatments with methyl-β-cyclodextrin or lipoprotein lipase have shown 10 
that changing the physicochemical properties of HCVcc29, 3028, 29, in which the peak 11 
density fraction containing HCVcc shifted higher, diminished the infectivity of the 12 
particles29, 30. As TXAS inhibitors did not show the apparent shift to a higher density (Fig. 13 
6), future molecular analyses of HCVcc particles should be required to reveal the 14 
underlying structural mechanisms for HCV infectivity.  15 
Prostanoids play various physiologic functions, including regulatory roles in muscle and 16 
blood vessels17. Although inhibition of TXAS decreased the infectivity of HCVcc (Fig. 3), 17 
the identity of the relevant prostanoid and how that product functions in the development 18 
of infectious HCV are currently unclear. As the treatment of PGH2, a substrate of TXAS, 19 
caused the increase of infectious HCV production (Supplemental Fig. 6), it seemed to 20 
be ruled out the possibility that supposedly accumulated PGH2 by the treatment of 21 
TXAS inhibitor play a role in the inhibition. Although we analyzed the total fatty acids in 22 
the HCV infected Huh-7.5 cells treated with and without Ozagrel, the compositions of 1 
fatty acids, including arachidonic acid (C20:4ω-6), were not largely different to each 2 
other (Supplemental Fig. 12), suggesting, at least, that the effect of Ozagrel is not due 3 
to major change of fatty acid composition. 4 
The activity of the TXAS product TXA2 was not directly examined, because its half-life 5 
is quite short31. Usually, TXA2 activity is measured using stable agonists and 6 
antagonists of TP. We showed, however, that TP-mediated signaling is not related to 7 
the processes examined in the current study (Fig.4) It seemed likely that TXA2 itself or 8 
an unidentified metabolite of TXA2 mediates the development of HCV infectivity in a TP-9 
independent manner. PGI2 and the PGD2 metabolite 15d-PGJ2 have been identified as 10 
ligands of PPAR δ and γ, respectively32, 33. Therefore, the TXAS product may act as a 11 
ligand of various nuclear receptors to regulate infectious HCV production. In the PHH 12 
and the liver of chimeric mice transplanted with human hepatocyte, the expression of 13 
human TP mRNA was not observed (Supplemental Fig. 3A and 13), although that was 14 
detected in human liver tissue, consisting of many types of cells (Supplemental Fig. 13). 15 
It may be true, therefore, that TP gene is not largely expressed in human hepatocytes in 16 
the liver as with Huh-7 cells. Taken together, it is probable that infectious HCV are 17 
produced in TP-independent manner in human liver infected with HCV. Further studies 18 
regarding the TP-independent roles of TXAS products in hepatocytes may be required 19 
to elucidate the mechanisms of infectious HCV formation. 20 
Recently, various drugs targeting viral proteins have been developed, resulting in more 21 
HCV-specific therapeutic profiles than those of conventional drugs34. Monotherapy with 22 
an HCV-specific drug, however, sometimes fails to clear the HCV infection because of 1 
rapidly emerging resistant variants35. We found that a TXAS inhibitor and IP agonists 2 
suppressed early-stage expansion of bbHCV post-infection of chimeric mice bearing 3 
human hepatocytes (Fig. 7). These results clearly indicate that the TXAS inhibitor and 4 
IP agonist are novel candidates for anti-HCV drugs. In this experiment, the effects of an 5 
IP agonist and the TXAS inhibitor were compared, because TXA2 and IP agonists have 6 
opposite clinical effects20. This implies that the IP agonist may have suppressed the 7 
effects of TXAS in the bbHCV-infected transplanted human hepatocytes. Contrary to our 8 
expectations, however, neither siRNA-mediated knockdown of PGIS expression nor 9 
treatment with the IP agonist Beraprost affected HCV genome replication, particle 10 
egression, or HCVcc infectivity (Supplemental Fig. 9). The responsiveness of Huh-7 11 
cells to the IP agonist was then examined by monitoring activation of cAMP signaling, a 12 
pathway that is normally activated downstream of IP. The results demonstrated that 13 
Huh-7 cells were deficient in signaling from IP to intracellular cAMP production 14 
(Supplemental Fig. 11). Although the therapeutic mechanism of action for the IP agonist 15 
in the chimeric mice has not been clarified yet, the IP agonist may signal through IP to 16 
counteract TXA2 signaling and suppress the effects of endogenous TXAS products on 17 
the formation of infectious HCV. In this in vivo experiments, the effect of drugs waned 18 
over time, especially in the case of Ozagrel. We examined the infectivity and the 19 
sensitivity against treatment with Ozagrel of HCV from the mice with the first drug 20 
treatment by secondary infection experiment. The results showed that HCV proliferated 21 
in the secondarily infected chimeric mice irrespective of the treatment of Ozagrel 22 
(Supplemental Fig. 14), suggesting that HCV proliferating in the chimeric mice with first 1 
treatment acquired the resistance against Ozagrel. We analyzed partial genomic 2 
sequences of the drug resistant HCVs by the direct sequencing method. We found that 3 
68 base substitutions, ten of which was accompanied with amino acid substitution, were 4 
present in such HCV genomes, compared to those in the mice untreated with the drug 5 
(Supplemental Fig. 15). This indicated that HCV, of which genome included a large 6 
number of base substitutions, actually proliferated in the chimeric mouse treated with 7 
Ozagrel. Further study of such drug resistant HCV, for examples, the reverse genetics 8 
analysis using recombinant HCV system, will help to reveal the molecular mechanisms 9 
of medicinal effect of this drug and the infectious HCV production. Furthermore, these 10 
results might demonstrate the needs to find the optimum dose of TXAS inhibitor for the 11 
effective therapy and to use this drug as one of options with different action mechanism 12 
for the multi-drug therapy. 13 
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Figure Legends. 1 
Figure 1. PG synthase mRNA expression under 3D culture conditions. (A) Results of 2 
microarray analysis. Black and white bars represent mRNA expression levels in HuS-3 
E/2 cells cultured with Mebiol gel and hollow fibers, respectively, relative to levels 4 
observed in cells cultured under 2D conditions. Gray bars represent mRNA expression 5 
levels in HuS-E/2 cells cultured with Mebiol gel by quantifying with quantitative RT-6 
PCRs. qRT-PCR data shows that averages from quadruplicate samples in two 7 
independent experiments ± SD are shown. * differs from Control, P < .01; ** differs from 8 
Control, P < .001. (B) Protein levels of TXAS and various PG synthases in 2D-cultured 9 
and 3D-cultured HuS-E/2 cells. PG synthases except for TXAS were detected in whole 10 
cell lysate. Asterisks show the result in membrane fraction. 11 
 12 
Figure 2. Effects of FR122047 on HCVcc-producing Huh-7 cells. (A) Effects of 13 
FR122047 on HCV RNA levels in cultured HCVcc-producing cells. HCV RNA was 14 
collected from the medium (black bars) and cells (white bars), which were treated with 15 
FR122047 at the indicated concentrations. Mean cell viability ± SD for each sample 16 
condition is also plotted (gray bars). Averages from quadruplicate samples in two 17 
independent experiments ± SD are shown. (B) Effects of FR122047 on the infectivity of 18 
HCVcc produced using this cell culture system. (C) FR122047 reduces infectious 19 
HCVcc in the culture medium. Huh-7.5 cells infected with HCVcc from the culture 20 
medium of cells treated with (right panel) and without (left panel) FR122047 at the 21 
indicated concentrations were stained with anti-HCV antibodies (magenta) and the 22 
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nuclear stain 4',6-diamidino-2-phenylindole (DAPI; cyan). Lower panels show infected 1 
cells at lower titer of inoculums. * differs from Control, P < .01; ** differs from Control, P 2 
< .001. 3 
 4 
Figure 3. Effect of TXAS on infectious HCV production. (A) siRNA-mediated knockdown 5 
of TXAS mRNA expression. (B) Effects of TXAS-specific siRNA on HCV RNA levels in 6 
the HCVcc-producing cell culture system. (C) Effects of control and TXAS-specific 7 
siRNA on the infectivity of HCVcc in medium obtained from HCVcc-producing cell 8 
cultures were assessed. (D) Effects of Ozagrel on HCV RNA levels were assessed in 9 
HCVcc-producing cell cultures. (E) Effects of Ozagrel on the infectivity of HCVcc 10 
produced from the cell culture system were assessed. * differs from Control, P < .01; ** 11 
differs from Control, P < .001. 12 
 13 
Figure 4. Role of TP in infectious HCVcc-producing cell cultures. (A) Effects of U-46619 14 
and TXB2 on HCV RNA levels in HCVcc-producing cell cultures in the presence of 15 
Ozagrel were assessed. (B) The infectivity of HCVcc in culture medium from HCVcc-16 
producing cells treated with U-46619 or TXB2 in the presence of Ozagrel was assessed. 17 
(C) Effect of daltroban on HCV RNA levels in HCVcc-producing cell cultures. (D) The 18 
infectivity of HCVcc in culture medium from HCVcc-producing cells treated with 19 
daltroban. * differs from Control, P < .01; ** differs from Control, P < .001. 20 
 21 
 22 
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Figure 5. Core and NS5A near LDs and the quantity and infectivity of intracellular 1 
HCVcc. (A) HCV Core (magenta) and NS5A (cyan) around LDs (yellow) in HCVcc-2 
producing cells treated with the indicated reagents were observed using 3 
immunofluorescence analysis. Nuclei were stained with DAPI (gray). Scale bars, 5 µm. 4 
(B) Levels of intracellular HCV RNA obtained from the cells treated with Ozagrel. (C) 5 
The infectivity of intracellular HCV from cells treated with Ozagrel. Averages of triplicate 6 
samples from two independent experiments ± SD are shown. ** differs from Control, P 7 
< .001. 8 
 9 
Figure 6. Buoyant density of HCVcc produced from cells treated with Ozagrel. Lower 10 
and upper panels show the results of HCVcc from the cells with and without Ozagrel 11 
treatment, respectively. HCV RNA (solid line), fraction density (dotted line) and HCV 12 
infectivity (white bars) in each fraction collected after ultracentrifugation are shown. 13 
Representative results from two independent experiments are shown.  14 
 15 
Figure 7. Effects of ONO1301, Beraprost, Ozagrel, and Telaprevir on the expansion of 16 
bbHCV-infected uPA/SCID mice bearing human hepatocytes. Data are presented as 17 
means ± SD for six (control, diamonds), four (ONO1301, squares; Ozagrel, crosses; 18 
Telaprevir, asterisk), and three (Beraprost, triangles) samples. * differs from Control, P 19 
< .05. 20 
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Supplemental Materials and Methods 1 
Preparation of subcellular fraction and protein detection with western blotting 2 
Subcellular fractions of HuS-E/2 cells and patient's tissues were prepared by use of 3 
ProteoExtract Subcellular proteome Extraction Kit (Millipore, Massachusetts, USA) 4 
according to manufacturerʼs protocol. Five µg of total protein of each fraction or whole 5 
cell lysate of each cells was analyze by western blotting. Western blotting was 6 
performed as described previously1.  7 
 8 
Collection of total RNA and cell lysate from HCV-infected patientsʼ tissue 9 
Total RNA from patientsʼ tissue was collected with RNeasy mini (Qiagen, Hilden, 10 
Germany). In briefly, frozen tissues were homogenized in lysis buffer with Power 11 
Masher (Nippi, Tokyo, Japan). Homogenized samples were used for RNA purification 12 
according to manufacturerʼs protocol. Cell lysate from tissues were collected with RIPA 13 
buffer (Thermo Scientific, Massachusetts, USA) or ProteoExtract Subcellular proteome 14 
Extraction Kit according to manufacturerʼs protocol. 15 
 16 
cAMP reporter assay 17 
Huh-7-derived and HuS-E/2 cells were transfected with pCRE-Luc (Agilent 18 
Technologies, California, USA) using Fugene6 (Roche) and Effectene (Qiagen, Hilden, 19 
Germany), respectively, essentially according to the manufacturersʼ protocols. Six hours 20 
and two days post-transfection of Huh-7–derived and HuS-E/2 cells, respectively, the 21 
culture medium was replaced with fresh medium containing one of the reagents. One 22 
and three day(s) post-transfection of Huh-7–derived and HuS-E/2 cells, respectively, 23 
luciferase activity in the cells was measured using a luciferase activity detection reagent 24 
(Promega, Wisconsin, USA) and Lumat LB 9507 luminometer (EG&G Berthold, Bad 25 
Wildbad, Germany). 26 
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 1 
Calcium ion quantification 2 
HEK293, Huh-7-derived, and HuS-E/2 cells were treated with the calcium ionosphere 3 
A23187 (Sigma-Aldrich) and the TXA2 receptor (TP) agonist U-46619 for 1 day. Calcium 4 
ion concentrations were quantified using a calcium assay kit (Cayman Chemical) 5 
according to the manufacturerʼs protocols. 6 
 7 
Actin polymerization assay 8 
An activation of actin polymerization via TP was measured with fluorescein 9 
isothiocyanate (FITC)-phalloidin (Sigma-Aldrich). After cultured in lipid-free fresh 10 
medium, cells were stimulated with 10 µM U46619 containing medium for 30, 60, and 11 
180 sec. Then, samples were stained with 10 µg/ml FITC-phalloidin, Fluorescent 12 
intensity at 520 nm was measured. 13 
 14 
Fatty acid analysis 15 
Fatty acid analysis of HCV-infected Huh7.5 cells treated with or without Ozagrel was 16 
performed by Toray Research Center, INC. in Japan using gas chromatogray. Total 17 
fatty acids samples were extracted from the cells according to Bligh-Dyer method2. 18 
 19 
Secondary infection experiments in chimeric mice transplanted human 20 
hepatocyte 21 
The chimeric mice were inoculated intravenously with patient serum including 1.0 x 105 22 
genome titer of bbHCV (genotype 1b) as the first infection. Ozagrel was orally 23 
administrated twice each day (300 µg/day) one week after the inoculation. The serum 24 
samples from those mice were collected at 5 weeks after starting the drug treatments, 25 
and used as inocula in the secondary infection experiment. Naïve chimeric mice were 26 
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inoculated with the collected chimeric mice serum including 1.0 x 105 genome titer of 1 
HCV. Administration of Ozagrel was started simultaneously. HCV RNA levels in the 2 
blood of the chimeric mice at 1, 2 and 3 weeks post infection in secondary infection 3 
experiments were evaluated by quantitative RT-PCR.	  4 
 5 
Determination of nucleotide sequence of HCV genome after the treatment of 6 
Ozagrel 7 
Chimeric mice were secondary inoculated with sera from HCV infected chimeric mice 8 
with or without the treatment of Ozagrel. Sera of these chimeric mice treated with or 9 
without Ozagrel were collected five weeks after the inoculation and the start of the 10 
treatment. HCV genome sequences of these samples were determined by the direct 11 
sequencing method according to the protocol described previously3. Obtained HCV 12 
genomic sequences from sera of mice with two different types of treatment were 13 
compared to each other. Mice with two different types of treatments were as follows; A. 14 
Mice inoculated secondarily with sera from 1st chimeric mouse without treatment were 15 
not treated with the drug (BankIt1626925 Seq3 in GenBank). B. Mice inoculated 16 
secondarily with sera from 1st chimeric mouse with treatment were treated with the drug 17 
(BankIt1626925 Seq1 in GenBank). These sequencing data were registered with 18 
GenBank (http://www.ncbi.nlm.nih.gov/genbank/). 19 
 20 
 21 
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Figure Legends 1 
Supplemental Figure 1. Protein and mRNA levels of PG synthases in HCV-infected 2 
patientʼs tissue. (A), (B) mRNA expression and protein levels of PG synthases in HCV-3 
infected patientʼs tissue. Representative results from two independent experiments are 4 
shown.  5 
 6 
Supplemental Figure 2. Effects of COX2 inhibitor 1 on infectious HCV production. (A) 7 
Effects of COX2 inhibitor 1 on HCV RNA levels in the HCVcc-producing cell culture 8 
system. Levels of HCV RNA in medium (black bars) and cells (white bars) treated with 9 
or without COX2 inhibitor 1 were assessed with quantitative RT-PCRs and are plotted 10 
as amounts relative to results observed with control cells (control). Mean cell viability ± 11 
SD for each sample condition is also plotted (gray bars). (B) Effects of COX2 inhibitor 1 12 
on the infectivity of HCVcc produced using the cell culture system. (C) Expression of 13 
COX2 mRNA in MH14 (positive control), Huh-7, and JFH1-transfected Huh-7 cells.  * 14 
differs from Control, P < .01; ** differs from Control, P < .001. 15 
 16 
Supplemental Figure 3. Expression of PG synthase and PG receptor mRNA in 17 
immortalized and primary hepatocyte cell lines. (A), (B) mRNA expression levels of 18 
various PG synthases and PG receptors in HuS-E/2 cells, Huh-7 cells, Huh-7.5 cells, 19 
and primary human hepatocytes were analyzed in RT-PCRs. Representative results 20 
from two independent experiments are shown. 21 
 22 
Supplemental Figure 4. Effects of short hairpin RNA (shRNA)-mediated knockdown of 23 
TXAS mRNA levels on infectious HCV production. (A) Knockdown of TXAS mRNA 24 
levels using shRNA. (B) Effects of TXAS-specific shRNA on HCV RNA levels in the 25 
HCVcc-producing cell culture system. Levels of HCV RNA in medium (black bars) and 26 
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cells (white bars) treated with control or TXAS-specific shRNA were assessed with 1 
quantitative RT-PCRs and are plotted as amounts relative to results observed with 2 
control shRNA–treated cells (control). Mean cell viability ± SD for each sample condition 3 
is also plotted (gray bars). (C) Effects of TXAS-specific shRNA on the infectivity of 4 
HCVcc produced using the cell culture system. ** differs from Control, P < .001. 5 
 6 
Supplemental Figure 5. Effects of Ozagrel and ONO1301 on the infectivity of HCVcc 7 
produced from J6/JFH1-transfected Huh-7.5 cells. (A) Effects of Ozagrel (upper panel) 8 
and ONO1301 (lower panel) on HCV RNA levels in HCVcc-producing cell cultures. 9 
Levels of HCV RNA in the medium (black bars) and cells (white bars) treated with 10 
Ozagrel or ONO1301 cells were assessed in quantitative RT-PCRs and are plotted as 11 
the amount relative to results from untreated cells (control). Mean cell viability ± SD for 12 
each sample condition is also plotted (gray bars). (B) Effects of Ozagrel (upper panel) 13 
and ONO1301 (lower panel) on the infectivity of HCVcc produced in the cell culture 14 
system. * differs from Control, P < .01; ** differs from Control, P < .001. 15 
 16 
Supplemental Figure 6. Effects of PGH2 on infectious HCV production. (A) Effects of 17 
PGH2 on HCV RNA levels in the HCVcc-producing cell culture system. Levels of HCV 18 
RNA in medium (black bars) and cells (white bars) treated with or without PGH2 were 19 
assessed with quantitative RT-PCRs and are plotted as amounts relative to results 20 
observed with control cells (control). Mean cell viability ± SD for each sample condition 21 
is also plotted (gray bars). (B) Effects of PGH2 on the infectivity of HCVcc produced 22 
using the cell culture system. * differs from Control, P < .01; ** differs from Control, P 23 
< .001. 24 
 25 
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Supplemental Figure 7. Effects of U-46619 and TXB2 on infectious HCV production. 1 
(A) Effects of U-46619 (upper panel) and TXB2 (lower panel) on HCV RNA levels in 2 
HCVcc-producing cell cultures. Levels of HCV RNA in the medium (black bars) and cells 3 
(white bars) treated with U-46619 or TXB2 were assessed in quantitative RT-PCRs and 4 
are plotted as the amount relative to results observed with untreated cells (control). 5 
Mean cell viability ± SD for each sample condition is also plotted (gray bars). (B) Effects 6 
of U-46619 (upper panel) and TXB2 (lower panel) on the infectivity of HCVcc produced 7 
in the cell culture system were assessed.  8 
 9 
Supplemental Figure 8. Effects of U-46619 on HuS-E/2, Huh-7, Huh-7.5, and HEK293 10 
cell lines via TP. (A) Concentrations of intracellular calcium ions were measured in HuS-11 
E/2 (black bars), Huh-7 (white bars), Huh-7.5 (gray bars), and HEK293 (dark gray bars) 12 
cells treated with or without a calcium ionophore or U-46619. Calcium ion 13 
concentrations relative to those in mock treated cells (control) were determined from 14 
triplicate wells in two independent experiments and are shown as means ± SD. (B) Actin 15 
polymerization after U-46619 treatment was measured with FITC-labeled phalloidin. * 16 
differs from Control, P < .01; ** differs from Control, P < .001 17 
 18 
Supplemental Figure 9. Effects of PGI2 on infectious HCV production. (A) siRNA-19 
mediated knockdown of PGIS expression. (B) Effects of PGIS-specific siRNA on HCV 20 
RNA levels in HCVcc-producing cell cultures. Levels of HCV RNA in medium (black 21 
bars) and cells (white bars) treated with control or PGIS-specific siRNA were assessed 22 
in quantitative RT-PCR and are plotted as amounts relative to results obtained with 23 
control siRNA–treated cells (control). Mean cell viability ± SD for each sample condition 24 
is also plotted (gray bars). (C) Effects of PGIS-specific siRNA on the infectivity of HCVcc 25 
produced in the cell culture system. (D) Effects of Beraprost on HCV RNA levels in 26 
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HCVcc-producing cell cultures. Levels of HCV RNA in medium (black bars) and HCVcc-1 
producing Huh-7 cells (white bars) treated with Beraprost were assessed in quantitative 2 
RT-PCRs and are plotted as amounts relative to results obtained with untreated cells 3 
(control). Mean cell viability ± SD for each sample condition is also plotted (gray bars). 4 
(E) Effects of Beraprost on the infectivity of HCVcc in culture medium from HCVcc-5 
producing cell cultures were assessed. * differs from Control, P < .01 6 
 7 
Supplemental Figure 10. Effects of ONO1301 on HCV lifecycle. (A) Levels of HCV 8 
RNA in medium (black bars) and cells (white bars) treated with or without ONO1301 9 
were assessed. Mean cell viability ± SD for each sample condition is also plotted (gray 10 
bars). (B) The infectivity of HCVcc in culture medium from HCVcc-producing cell 11 
cultures treated with or without ONO1301 was assessed. (C) Subcellular locations of 12 
HCV Core and NS5A proteins around LDs in the presence of ONO1301. Scale bars, 5 13 
µm. (D), (E) Levels and infectivity of intracellular HCV obtained from the cells treated 14 
with ONO1301. (F) Buoyant density of HCVcc obtained using cells treated with 15 
ONO1301. The panel shows HCV RNA (solid line), fraction density (dotted line) and 16 
HCV infectivity (white bars) in each fraction collected by ultracentrifugation. * differs 17 
from Control, P < .01; ** differs from Control, P < .001. 18 
 19 
Supplemental Figure 11. Effects of dibutyryl cAMP (dbcAMP) on cell cultures 20 
producing JFH1 HCVcc. (A) HuS-E/2 (black bars), Huh-7 (white bars), and Huh-7.5 21 
(gray bars) cells were transfected with CRE-Luc plasmid. Then, the luciferase activity in 22 
each sample was measured. Values were obtained from quadruplicate wells in two 23 
independent experiments and are shown as means ± SD. (B) Effects of dbcAMP on 24 
HCV RNA levels in HCVcc-producing cell cultures. Levels of HCV RNA in medium 25 
(black bars) and cells treated with dbcAMP (white bars) were assessed in quantitative 26 
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RT-PCRs and are plotted as amounts relative to results obtained with mock-treated 1 
cells (control). Mean cell viability ± SD for each sample condition is also plotted (gray 2 
bars). (C) Effects of dbcAMP on the infectivity of HCVcc produced using the cell culture 3 
system. * differs from Control, P < .01; ** differs from Control, P < .001. 4 
 5 
Supplemental Figure 12. Comparison of composition of fatty acids in HCV-infected 6 
Huh7.5 cells with or without the treatment of Ozagrel. 7 
 8 
Supplemental Figure 13. Expression of TP mRNA in liver tissues from Human patients 9 
and chimeric mice infected with HCV. 10 
 11 
Supplemental Figure 14. Secondary infection of HCV derived from chimeric mice 12 
model. Data are presented as means ± SD for four samples.  13 
 14 
Supplemental Figure 15. Base substitutions in HCV genome collected from mice 15 
serum during secondary infection. HCV genomic sequences from mice sera with the 16 
treatment of Ozagrel during primary and secondary infection was compared to those 17 
from mice without any treatment during both infection experiments. The region of 18 
obtained HCV genomic sequences is indicated by a thick bar. The nucleotide positions 19 
of each base substitution are shown with arrows.  Positions of base substitutions, and 20 
types of base substitution and amino acid replacement are listed at lower panel.  21 
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Tables 1 
Supplemental Table 1. Primer sequences and parameters in RT-PCR experiments. 2 
RT-PCRs were performed as follows: 25–40 cycles of 95°C for 30 seconds, 55–62°C for 3 
30 seconds, and 72°C for 1 minute. 4 
 5 
Supplemental Table 2. Primer sequences and parameters in qRT-PCR experiments. 6 
qRT-PCRs were performed as follows: 40 cycles of 95°C for 5 seconds, 60°C for 34 7 
seconds. 8 
 9 
Supplemental Reference 10 
1. Kushima Y, Wakita T, Hijikata M. A disulfide-bonded dimer of the core protein of 11 
hepatitis C virus is important for virus-like particle production. J Virol 12 
2010;84:9118-9127. 13 
2. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J 14 
Biochem Physiol 1959;37:911-917. 15 
3. Kimura T, Imamura M, Hiraga N, et al. Establishment of an infectious genotype 16 
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Genes Primer Sequence 5'-3' 
Product 
Size (bp) 
99 
104 
123 
83 
151 
129 
GAPDH 
F: TCCGGTTCTTGCTGTTCCTG 
R: TCACACTGGTAGCGGTCAAG 
F: CATCCTCTCCCTGGAAATCTCG 
R: CCGCTTCCTACTGTGACCC 
F: CCTGTCCACCTTGCACAGTC 
R: TCATGCTTCGGTTCAGGACG 
F: GCAGTGTCAAAAGTCGCCTG 
R: ACTCTCCAGCCATTTGCTCC 
F: TTTGCTTGGTTGCCTGTTCC 
R: CCAGAGTGGTGGTCTTCCAG 
F: GACAGTCAGCCGCATCTTCT 
R: GCGCCCAATACGACCAAATC 
COX1 
PGES 
PGDS 
PGIS 
TXAS 
